<DOC>
	<DOCNO>NCT01774851</DOCNO>
	<brief_summary>To determine whether combination MM-111 plus paclitaxel trastuzumab effective paclitaxel trastuzumab alone</brief_summary>
	<brief_title>A Study MM-111 Paclitaxel With Trastuzumab Patients HER2 Positive Carcinomas Distal Esophagus , Gastroesophageal ( GE ) Junction Stomach</brief_title>
	<detailed_description>This randomize , open Label , Phase 2 Study MM-111 Paclitaxel withTrastuzumab Patients HER2 Positive Carcinomas Distal Esophagus , Gastroesophageal ( GE ) Junction Stomach Who Have Failed Front Line Metastatic Locally Advanced Therapy . Approximately 120 patient randomize 1:1 ratio experimental comparator arm .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients must documentation histologically cytologically confirm metastatic locally advanced adenocarcinoma distal esophagus , GE junction stomach Patients must documentation histologically cytologically confirm HER2 expression Patients must ≥18 year age Patients must ECOG PS 0 , 1 , 2 Patients must adequate hematologic status , renal hepatic function Patients know hypersensitivity component MM111 Patients known history hypersensitivity paclitaxel drug formulate Cremophor® EL Patients known history hypersensitivity trastuzumab component ( group 1 patient ) Patients active infection unexplained fever &gt; 38.5°C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HER-2 Gene Amplification</keyword>
	<keyword>Esophagus Cancer</keyword>
	<keyword>Gastroesophageal Junction Cancer</keyword>
	<keyword>Stomach Cancer</keyword>
	<keyword>Her2 Positive</keyword>
	<keyword>Her2+</keyword>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Metastatic</keyword>
</DOC>